Concepedia
Statistics
Publications
11
Citations
837
H-Index
Active since
2009
Affiliations
Institute of Cancer Research(Current)
Eli Lilly (United Kingdom)
Cancer Research UK
University of Oxford
Eli Lilly (United States)
Lewis R. Vidler is an author at Institute of Cancer Research specializing in drug discovery, drug design, and medicinal chemistry.
Publications per year
2009–2020
Druggability Analysis and Structural Classification of Bromodomain Acetyl-lysine Binding Sites
Lewis R. Vidler, Nathan Brown, Stefan Knapp et al. · Journal of Medicinal Chemistry · 2012 · 273 citations · Full text
Pharmacy, Medicinal Chemistry, Molecular Biology +15
Discovery of Novel Small-Molecule Inhibitors of BRD4 Using Structure-Based Virtual Screening
Lewis R. Vidler, P. Filippakopoulos, O. Fedorov et al. · Journal of Medicinal Chemistry · 2013 · 127 citations · Full text
Pharmacy, Medicinal Chemistry, Pharmacology +17
Structure Enabled Design of BAZ2-ICR, A Chemical Probe Targeting the Bromodomains of BAZ2A and BAZ2B
Ludovic Drouin, Sally McGrath, Lewis R. Vidler et al. · Journal of Medicinal Chemistry · 2015 · 101 citations · Full text
Life Sciences, Medicinal Chemistry, Pharmacology +14
Epilepsy-associated GRIN2A mutations reduce NMDA receptor trafficking and agonist potency – molecular profiling and functional rescue
Laura Addis, Jasmeet Virdee, Lewis R. Vidler et al. · Scientific Reports · 2017 · 94 citations · Full text
Life Sciences, Neuroscience, Pharmacology +17
Changing the local coordination environment in mono- and bi- nuclear lanthanide complexes through “click” chemistry
Maite Jauregui, William S. Perry, Clémence Allain et al. · Dalton Transactions · 2009 · 75 citations
Natural Sciences, Chemistry, Inorganic Chemistry +16
1–5 of 11